Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Alcon Yönetim

Yönetim kriter kontrolleri 3/4

Alcon's CEO'su David Endicott, Jul2018 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 12.33M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.7% maaş ve 89.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.047% ine doğrudan sahiptir ve bu hisseler CHF 19.60M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.9 yıl ve 5.8 yıldır.

Anahtar bilgiler

David Endicott

İcra Kurulu Başkanı

US$12.3m

Toplam tazminat

CEO maaş yüzdesi	10.7%
CEO görev süresi	6.3yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	4.9yrs
Yönetim Kurulu ortalama görev süresi	5.8yrs

Son yönetim güncellemeleri

Recent updates

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Feb 15

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Dec 22

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Dec 04

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Nov 08

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Oct 18

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Aug 25

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Aug 10

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Jul 05

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

May 12

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Apr 03

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Feb 03

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Jan 19

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Dec 18

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Nov 02

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

Sep 30

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

Sep 11

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Aug 26

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

Jun 10

Alcon (VTX:ALC) Is Experiencing Growth In Returns On Capital

May 20

There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital

Feb 13

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Dec 28

We Like These Underlying Return On Capital Trends At Alcon (VTX:ALC)

Oct 26

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Sep 15

CEO Tazminat Analizi

David Endicott'un ücretlendirmesi Alcon'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$12m	US$1m	US$974m
Sep 30 2023	n/a	n/a	US$450m
Jun 30 2023	n/a	n/a	US$362m
Mar 31 2023	n/a	n/a	US$341m
Dec 31 2022	US$10m	US$1m	US$335m
Sep 30 2022	n/a	n/a	US$571m
Jun 30 2022	n/a	n/a	US$457m
Mar 31 2022	n/a	n/a	US$460m
Dec 31 2021	US$11m	US$1m	US$376m
Sep 30 2021	n/a	n/a	US$332m
Jun 30 2021	n/a	n/a	US$183m
Mar 31 2021	n/a	n/a	-US$390m
Dec 31 2020	US$8m	US$1m	-US$531m
Sep 30 2020	n/a	n/a	-US$717m
Jun 30 2020	n/a	n/a	-US$636m
Mar 31 2020	n/a	n/a	-US$604m
Dec 31 2019	US$7m	US$1m	-US$656m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 12.33M ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.82M ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Endicott (59 yo)

6.3yrs

Görev süresi

US$12,325,391

Tazminat

Mr. David J. Endicott is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. He is the C...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% $ 4.6m
David Endicott	CEO & Director	6.3yrs	US$12.33m	0.047% $ 19.1m
Arthur Cummings	Executive Director	no data	US$284.68k	0.0012% $ 474.7k
Timothy Stonesifer	Chief Financial Officer	5.5yrs	Veri yok	0.020% $ 8.0m
Ian Bell	Senior VP & COO	less than a year	Veri yok	0.0081% $ 3.3m
Margaret Buckley	Chief Accounting Officer	no data	Veri yok	Veri yok
Franck Leveiller	Senior VP	2.3yrs	Veri yok	Veri yok
Royce Bedward	Senior VP	no data	Veri yok	Veri yok
Kimberly Martin	Senior VP	4.3yrs	Veri yok	Veri yok
Laurent Attias	Head of Corporate Development	no data	Veri yok	0.0040% $ 1.6m
Leon Sergio Fraustro	President of North America	9.2yrs	Veri yok	0.0043% $ 1.7m
Ed McGough	Senior VP and Head of Global Manufacturing & Technical Operations	no data	US$2.03m	Veri yok

4.9yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: ALC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% $ 4.6m
David Endicott	CEO & Director	5.8yrs	US$12.33m	0.047% $ 19.1m
Arthur Cummings	Executive Director	5.8yrs	US$284.68k	0.0012% $ 474.7k
Karen May	Independent Director	5.8yrs	US$325.52k	0.0052% $ 2.1m
D. Grossman	Independent Vice Chair	5.8yrs	US$361.69k	0.0031% $ 1.2m
Thomas Glanzmann	Independent Director	5.8yrs	US$352.98k	0.0041% $ 1.7m
Dieter Spälti	Independent Director	5.8yrs	US$236.83k	0.0049% $ 2.0m
Scott Maw	Independent Director	5.8yrs	US$333.87k	0.0031% $ 1.2m
Lynn Bleil	Independent Director	5.8yrs	US$296.31k	0.0019% $ 791.1k
Ines Pöschel	Independent Director	5.8yrs	US$293.86k	0.0021% $ 860.1k
RaQuel Bono	Independent Director	2.5yrs	US$256.66k	0.00057% $ 231.2k

5.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).

Alcon Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO & Director notifies of intention to sell stock

Alcon Announces Management Changes

President of North America notifies of intention to sell stock

Alcon Inc., Annual General Meeting, May 08, 2024

Head of Corporate Development notifies of intention to sell stock

Alcon Inc., Annual General Meeting, May 05, 2023

Recent updates

CEO & Director notifies of intention to sell stock

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 24% undervalued

Investor Optimism Abounds Alcon Inc. (VTX:ALC) But Growth Is Lacking

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

Should You Be Adding Alcon (VTX:ALC) To Your Watchlist Today?

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

First quarter 2024 earnings: EPS exceeds analyst expectations

Upcoming dividend of CHF0.24 per share

Alcon Inc. Approves Gross Dividend

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit

Alcon Announces Management Changes

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

President of North America notifies of intention to sell stock

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Head of Corporate Development notifies of intention to sell stock

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Now 20% undervalued

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations